Aptar strengthens portfolio with Noble acquisition

Drug delivery solutions provider AptarGroup has announced it has acquired Noble International, a provider of drug delivery training devices.

The acquisition is intended to strengthen Aptar’s portfolio of services that support pharmaceutical and biotech customers through all stages of their drug development process.

Noble develops patient-centric advanced drug delivery system training devices to help improve the administration of medications. The company’s devices mimic the feel, force and function of the actual drug delivery device and are designed to reduce error and increase device familiarity, both of which are keys to helping patients improve adherence and, ultimately, health outcomes.

For instance, Noble has developed a connected solution for injectable devices, which senses and monitors how a patient interacts with the specific steps of drug delivery and can wirelessly transmit real-time data.

Stephan Tanda, Aptar President and CEO, said: “We are pleased to welcome the Noble team to the Aptar family. This strategic acquisition meets our disciplined approach of acquiring companies with strong positions in attractive markets, proprietary technologies and robust growth fundamentals. The combination of Noble and Aptar will bring additional value to our pharmaceutical customers as they seek to put more life-changing treatments into the hands of empowered patients. Together, we will work toward the ultimate goal of improving patient experiences and health outcomes.”

“Joining Aptar is an important step in our mission to support the healthcare community’s effort to improve patient outcomes through innovation, education and patient access,” said Jeff Baker, Noble CEO. “It is exciting to know that by leveraging the breadth of Aptar’s portfolio and global network, we will now reach more pharmaceutical partners, healthcare professionals, caregivers and, ultimately, patients.”